Data from the Phase II trial of intermittent androgen suppression for men in biochemical recurrence after radiotherapy for locally advanced prostate cancer by Bruchovsky et al (2006).

These are the data from the Phase II study by Bruchovsky et al on intermittent androgen deprivation therapy which were previously available on the author's webpage (http://www.nicholasbruchovsky.com/clinicalResearch.html). Sadly, Nicholas Bruchovsky passed away in 2015, and the webpage has subsequently been taken down. As these data have driven numerous research studies, including our most recent one about to be published in Communications Medicine, we have decided to archive these data on Figshare, so that they may continue to drive research in the memory of Dr Bruchovsky. We emphasize that we do not hold ownership of these data, and that all questions about their collection and use should be directed towards the original study team. <br><br>Details on the study can be found in the following publications:<br>- Bruchovsky N, Klotz LH, Sadar M, Crook JM, Hoffart D, Godwin L, Warkentin M, Gleave ME, Goldenberg SL. Intermittent androgen suppression for prostate cancer: Canadian Prospective Trial and related observations. Mol Urol. 2000 Fall;4(3):191-9;discussion 201. PMID: 11062374.- Bruchovsky, N., Klotz, L., Crook, J., Malone, S., Ludgate, C., Morris, W. J., Gleave, M. E., &amp; Goldenberg, S. L. (2006). Final results of the Canadian prospective Phase II trial of intermittent androgen suppression for men in biochemical recurrence after radiotherapy for locally advanced prostate cancer: Clinical parameters. <i>Cancer</i>, <i>107</i>(2), 389–395. https://doi.org/10.1002/cncr.21989- Bruchovsky N, Klotz L, Crook J, Goldenberg SL. Locally advanced prostate cancer--biochemical results from a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen recurrence after radiotherapy. Cancer. 2007 Mar 1;109(5):858-67. doi: 10.1002/cncr.22464. PMID: 17265527.